Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects

Chung Hung Shih, Ling Hong Lin, Ya Hsin Lai, Chi Yin Lai, Cheng Ying Han, Chien Ming Chen, Wun-Chang Ko

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The affinities of genistein on phosphodiesterase (PDE)1-4 and cause of gastrointestinal adverse effects of genistein remain unclear. Female BALB/c mice were actively sensitized by intraperitoneal injections of ovalbumin and challenged by aerosolized ovalbumin (1%). After secondary challenge, aerosolized methacholine (6.25-50mg/ml) induced increases of enhanced pause (P enh) values in conscious mice in a concentration-dependent manner. Genistein (30-100μmol/kg, i.p.) markedly inhibited methacholine (12.5-50mg/ml)-induced increase of P enh value in the sensitized and challenged mice. In addition, genistein significantly reduced total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid, with the exception that lymphocytes and neutrophils were not significantly inhibited by genistein at the lowest dose (10μmol/kg). Genistein also markedly attenuated the release of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Genistein competitively inhibited PDE1-4, with a K i value ranging from 4.3 to 13.7μM. Genistein (3-300μM) concentration-dependently displaced 2nM [ 3H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes. The therapeutic ratio of genistein was calculated to be 7.9. Genistein (100μmol/kg, s.c.) significantly shortened xylazine/ketamine-induced anesthesia, suggesting that genistein administered at a higher dose may have gastrointestinal adverse effects. In conclusion, owing to the low therapeutic ratio of genistein, the gastrointestinal adverse effects may be induced via the binding of genistein on high-affinity rolipram binding sites of brain cell membranes, when it is used for a long term or at higher doses for treating allergies, asthma or chronic obstructive pulmonary disease.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalEuropean Journal of Pharmacology
Volume643
Issue number1
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Rolipram
Genistein
Binding Sites
Cell Membrane
Brain
Methacholine Chloride
Ovalbumin
Neutrophils
Type 4 Cyclic Nucleotide Phosphodiesterase
Lymphocytes
Xylazine
Interleukin-5
Bronchoalveolar Lavage Fluid
Ketamine
Intraperitoneal Injections
Eosinophils
Interleukin-4
Chronic Obstructive Pulmonary Disease
Interferons

Keywords

  • Allergic asthma
  • Cytokine
  • Gastrointestinal adverse effect
  • Genistein
  • High-affinity rolipram binding site
  • Phosphodiesterase isozymes 1-4 inhibition

ASJC Scopus subject areas

  • Pharmacology

Cite this

Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects. / Shih, Chung Hung; Lin, Ling Hong; Lai, Ya Hsin; Lai, Chi Yin; Han, Cheng Ying; Chen, Chien Ming; Ko, Wun-Chang.

In: European Journal of Pharmacology, Vol. 643, No. 1, 09.2010, p. 113-120.

Research output: Contribution to journalArticle

Shih, Chung Hung ; Lin, Ling Hong ; Lai, Ya Hsin ; Lai, Chi Yin ; Han, Cheng Ying ; Chen, Chien Ming ; Ko, Wun-Chang. / Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects. In: European Journal of Pharmacology. 2010 ; Vol. 643, No. 1. pp. 113-120.
@article{8041ac74f0114ec288fd510e48f012a8,
title = "Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects",
abstract = "The affinities of genistein on phosphodiesterase (PDE)1-4 and cause of gastrointestinal adverse effects of genistein remain unclear. Female BALB/c mice were actively sensitized by intraperitoneal injections of ovalbumin and challenged by aerosolized ovalbumin (1{\%}). After secondary challenge, aerosolized methacholine (6.25-50mg/ml) induced increases of enhanced pause (P enh) values in conscious mice in a concentration-dependent manner. Genistein (30-100μmol/kg, i.p.) markedly inhibited methacholine (12.5-50mg/ml)-induced increase of P enh value in the sensitized and challenged mice. In addition, genistein significantly reduced total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid, with the exception that lymphocytes and neutrophils were not significantly inhibited by genistein at the lowest dose (10μmol/kg). Genistein also markedly attenuated the release of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Genistein competitively inhibited PDE1-4, with a K i value ranging from 4.3 to 13.7μM. Genistein (3-300μM) concentration-dependently displaced 2nM [ 3H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes. The therapeutic ratio of genistein was calculated to be 7.9. Genistein (100μmol/kg, s.c.) significantly shortened xylazine/ketamine-induced anesthesia, suggesting that genistein administered at a higher dose may have gastrointestinal adverse effects. In conclusion, owing to the low therapeutic ratio of genistein, the gastrointestinal adverse effects may be induced via the binding of genistein on high-affinity rolipram binding sites of brain cell membranes, when it is used for a long term or at higher doses for treating allergies, asthma or chronic obstructive pulmonary disease.",
keywords = "Allergic asthma, Cytokine, Gastrointestinal adverse effect, Genistein, High-affinity rolipram binding site, Phosphodiesterase isozymes 1-4 inhibition",
author = "Shih, {Chung Hung} and Lin, {Ling Hong} and Lai, {Ya Hsin} and Lai, {Chi Yin} and Han, {Cheng Ying} and Chen, {Chien Ming} and Wun-Chang Ko",
year = "2010",
month = "9",
doi = "10.1016/j.ejphar.2010.06.026",
language = "English",
volume = "643",
pages = "113--120",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects

AU - Shih, Chung Hung

AU - Lin, Ling Hong

AU - Lai, Ya Hsin

AU - Lai, Chi Yin

AU - Han, Cheng Ying

AU - Chen, Chien Ming

AU - Ko, Wun-Chang

PY - 2010/9

Y1 - 2010/9

N2 - The affinities of genistein on phosphodiesterase (PDE)1-4 and cause of gastrointestinal adverse effects of genistein remain unclear. Female BALB/c mice were actively sensitized by intraperitoneal injections of ovalbumin and challenged by aerosolized ovalbumin (1%). After secondary challenge, aerosolized methacholine (6.25-50mg/ml) induced increases of enhanced pause (P enh) values in conscious mice in a concentration-dependent manner. Genistein (30-100μmol/kg, i.p.) markedly inhibited methacholine (12.5-50mg/ml)-induced increase of P enh value in the sensitized and challenged mice. In addition, genistein significantly reduced total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid, with the exception that lymphocytes and neutrophils were not significantly inhibited by genistein at the lowest dose (10μmol/kg). Genistein also markedly attenuated the release of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Genistein competitively inhibited PDE1-4, with a K i value ranging from 4.3 to 13.7μM. Genistein (3-300μM) concentration-dependently displaced 2nM [ 3H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes. The therapeutic ratio of genistein was calculated to be 7.9. Genistein (100μmol/kg, s.c.) significantly shortened xylazine/ketamine-induced anesthesia, suggesting that genistein administered at a higher dose may have gastrointestinal adverse effects. In conclusion, owing to the low therapeutic ratio of genistein, the gastrointestinal adverse effects may be induced via the binding of genistein on high-affinity rolipram binding sites of brain cell membranes, when it is used for a long term or at higher doses for treating allergies, asthma or chronic obstructive pulmonary disease.

AB - The affinities of genistein on phosphodiesterase (PDE)1-4 and cause of gastrointestinal adverse effects of genistein remain unclear. Female BALB/c mice were actively sensitized by intraperitoneal injections of ovalbumin and challenged by aerosolized ovalbumin (1%). After secondary challenge, aerosolized methacholine (6.25-50mg/ml) induced increases of enhanced pause (P enh) values in conscious mice in a concentration-dependent manner. Genistein (30-100μmol/kg, i.p.) markedly inhibited methacholine (12.5-50mg/ml)-induced increase of P enh value in the sensitized and challenged mice. In addition, genistein significantly reduced total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid, with the exception that lymphocytes and neutrophils were not significantly inhibited by genistein at the lowest dose (10μmol/kg). Genistein also markedly attenuated the release of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Genistein competitively inhibited PDE1-4, with a K i value ranging from 4.3 to 13.7μM. Genistein (3-300μM) concentration-dependently displaced 2nM [ 3H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes. The therapeutic ratio of genistein was calculated to be 7.9. Genistein (100μmol/kg, s.c.) significantly shortened xylazine/ketamine-induced anesthesia, suggesting that genistein administered at a higher dose may have gastrointestinal adverse effects. In conclusion, owing to the low therapeutic ratio of genistein, the gastrointestinal adverse effects may be induced via the binding of genistein on high-affinity rolipram binding sites of brain cell membranes, when it is used for a long term or at higher doses for treating allergies, asthma or chronic obstructive pulmonary disease.

KW - Allergic asthma

KW - Cytokine

KW - Gastrointestinal adverse effect

KW - Genistein

KW - High-affinity rolipram binding site

KW - Phosphodiesterase isozymes 1-4 inhibition

UR - http://www.scopus.com/inward/record.url?scp=77955085786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955085786&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2010.06.026

DO - 10.1016/j.ejphar.2010.06.026

M3 - Article

VL - 643

SP - 113

EP - 120

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -